AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Alpine Immune Sciences to Present at Upcoming Investor Conferences

May 24, 2019

SEATTLE--(BUSINESS WIRE)--May 24, 2019--

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming investor conferences in June.

Jefferies 2019 Healthcare Conference

Date: Thursday, June 6, 2019

Time: 2:00 p.m. Eastern Time

Location: New York, NY

Raymond James Life Sciences and MedTech Conference

Date: Wednesday, June 19, 2019

Time: 1:15 p.m. Eastern Time

Location: New York, NY

JMP Securities Life Sciences Conference

Date: Thursday, June 20, 2019

Time: 1:30 p.m. Eastern Time

Location: New York, NY

A live webcast of each presentation will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients’ lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. ALPN-101 is currently enrolling a Phase I healthy volunteer trial. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation - an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190524005014/en/

CONTACT: Investor Relations:

Pure Communications

Courtney Dugan, 212-257-6723

cdugan@purecommunications.comMedia Relations:

Pure Communications

Jennifer Paganelli, 347-658-8290

jpaganelli@purecommunications.com

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Alpine Immune Sciences, Inc.

Copyright Business Wire 2019.

PUB: 05/24/2019 07:35 AM/DISC: 05/24/2019 07:35 AM

http://www.businesswire.com/news/home/20190524005014/en